A Study of IDP-001 in Advanced or Metastatic Solid Tumors

This clinical study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of IDP-001 in participants with advanced or metastatic squamous and non-squamous NSCLC and other squamous cell solid tumors (for example, head and neck, esophageal, cervical, cutaneous).

Trial Details

NCT ID
NCT07602842
Phase
PHASE1 / PHASE2
Sponsor
InduPro, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • IDP-001
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sarasota, Florida, United States|27.33643,-82.53065
  • Indianapolis, Indiana, United States|39.76838,-86.15804
  • Buffalo, New York, United States|42.88645,-78.87837
  • Lake Success, New York, United States|40.77066,-73.71763

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Histologically-confirmed advanced, metastatic, or recurrent solid tumors that is not amenable to surgical resection or other approved therapeutic o…
  • Satisfy requirements for prior treatments per tumor type as outlined in the protocol
  • Measurable disease per RECIST v1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →